VXRT

Vaxart

VXRT

Market cap $73M

Overview Fund Activity

Delisted

VXRT was delisted on the 7th of July, 2025.

Back to rankings

About: Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Employees: 105

Healthcare Biotechnology

Financial journalist opinion

Vaxart Appoints W. Mark Watson as Lead Independent Director

In process of adopting a Director stock ownership policy to reinforce commitment of aligning the Board's interests with stockholders

Vaxart Appoints W. Mark Watson as Lead Independent Director

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

- Second-generation constructs induce robust increases in fecal IgA, which was shown to be correlated with protection against infection in the company's previous Phase 2b challenge study -

Vaxart Reports Additional Phase 1 Data Supporting the Potential Efficacy of its Second-Generation Norovirus Oral Pill Vaccine Candidate

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Question Board's Repeated Delay Tactics and Demand Transparency on Voting Results, Nasdaq Compliance and Governance Changes

Concerned Vaxart Stockholders Condemn Board's Decision to Adjourn Reverse Stock Split Vote at Special Meeting

Vaxart Announces Adjournment of Special Meeting of Stockholders

Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and future potential disclosures Vaxart encourages all stockholders of record on July 29, 2025 who have not yet voted to do so by 11:59 p.m.

Vaxart Announces Adjournment of Special Meeting of Stockholders

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced that its Chairman, Michael J. Finney, Ph.D., has announced his retirement from the Company's Board of Directors and Science and Technology Committee after a distinguished tenure of service. His retirement will be effective September 30, 2025.

Vaxart Announces Retirement of Chairman Michael J. Finney, Ph.D.

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition Oppose Management's Latest Attempt to Push Through Proposal Despite Prior Overwhelming Stockholder Opposition

Concerned Vaxart Stockholders Urge Fellow Stockholders to Vote “AGAINST” Reverse Stock Split and Demand Board Accountability

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

Urge Stockholders to Vote “AGAINST” Reverse Stock Split at Upcoming Special Meeting Call for Accountability Given Board's Pattern of Disregarding Stockholders' Will and Value-Destructive Capital Allocation Decisions ATLANTA, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Richard John Burgess, Daniel P. Houle, Michael Patrick Kelley, Marc Eustace Pereira, Patrice Raffy, Benjamin Sauv, Matthew M.

Concerned Vaxart Stockholders Unite to Oppose Vaxart's Latest Reverse Stock Split and Defend Stockholder Rights

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

Vaxart, Inc. (OTC:VXRT) Q2 2025 Earnings Conference Call August 13, 2025 4:30 PM ET Company Participants Edward B. Berg - Senior VP & General Counsel James F.

Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript

Zacks Investment Research

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

VAXART, INC. (VXRT) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.09.

VAXART, INC. (VXRT) Reports Q2 Loss, Beats Revenue Estimates

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

Vaxart said on Wednesday it received an order to stop work on screening and enrollment for its COVID-19 mid-stage trial, joining multiple biotech companies that have lost government funding for their vaccine programs.

US orders Vaxart to stop COVID-19 trial amid mRNA wind down

See News Rankings

Charts implemented using Lightweight Charts™